CHMP recommends Diurnal's Alkindi for pediatric adrenal insufficiency

EMA's CHMP recommended approval of Alkindi (Infacort) from Diurnal Ltd. (Cardiff, U.K.) as replacement therapy for pediatric adrenal insufficiency. The company expects a final decision in February and anticipates a launch in 2Q18...